SNORD74: A Potential Drug Target and Biomarker (G619498)

Target Name: SNORD74

NCBI ID: G619498

SNORD74

Other Name(s): Small nucleolar RNA, C/D box 74 | SNORD74A | U74 | small nucleolar RNA, C/D box 74 | Z18

SNORD74: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the most well-known snRNAs is SNORD74, which is located in the C/D box on chromosome 8 and is composed of 74 amino acids.

SNORD74 is a key regulator of gene expression and has been involved in the regulation of various cellular processes, including cell growth, apoptosis, and translation of RNA into proteins. Its function as a regulator of gene expression makes it an attractive drug target and a potential biomarker for various diseases.

Drugs that target SNORD74 have the potential to treat a wide range of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because SNORD74 is involved in the regulation of a wide range of cellular processes, including cell growth, apoptosis, and translation of RNA into proteins, making it a potential target for drugs that affect these processes.

One of the most promising SNORD74 drug targets is its role in the regulation of cell apoptosis. SNORD74 has been shown to play a role in the regulation of apoptosis in various cell types, including cancer cells. Researchers have found that SNORD74 levels are elevated in cancer cells and that inhibiting its function can lead to the inhibition of cell apoptosis. This suggests that SNORD74 may be an effective target for cancer treatments that target apoptosis.

Another promising SNORD74 drug target is its role in the regulation of translation of RNA into proteins. SNORD74 is involved in the regulation of the translation of RNA into proteins and has been shown to play a role in the regulation of protein synthesis in various cell types. Researchers have found that SNORD74 levels are elevated in various diseases, including neurodegenerative diseases, and that inhibiting its function can lead to the translation of RNA into proteins. This suggests that SNORD74 may be an effective target for treatments that target protein synthesis in diseases such as neurodegenerative diseases.

In addition to its potential as a drug target, SNORD74 is also a potential biomarker for various diseases. Its role in the regulation of gene expression makes it an attractive target for diagnostic tests that detect changes in gene expression levels. Researchers have found that SNORD74 levels are elevated in a wide range of diseases, including neurodegenerative diseases, cancer, and autoimmune disorders. This suggests that SNORD74 may be a useful biomarker for these diseases and that its levels can be used as a diagnostic target.

In conclusion, SNORD74 is a promising drug target and biomarker for various diseases. Its role in the regulation of cell apoptosis and translation of RNA into proteins makes it an attractive target for drugs that affect these processes. Further research is needed to fully understand the role of SNORD74 in disease and to develop effective treatments.

Protein Name: Small Nucleolar RNA, C/D Box 74

The "SNORD74 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD74 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets